Company intelligence / Profile preview
SicaGene
Seongnam-si, Gyeonggi-do, South Koreasicagene.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
SicaGene is a South Korean biotechnology company focused on developing innovative RNA interference (RNAi) therapeutics. The company utilizes its proprietary Sica-siRNA platform technology to design small interfering RNAs with improved stability, potency, and reduced off-target effects. SicaGene's primary therapeutic focus is on liver-related diseases, including metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis, as well as oncology. Its lead programs, such as SG-101 and SG-201, are currently in the preclinical stage of development. The company aims to address significant unmet medical needs by providing targeted genetic medicines that can silence disease-causing genes with high precision.
- Therapeutic areas
- OncologyMetabolic DisordersGastroenterology
- Modalities
- Small interfering RNARNA therapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on SicaGene.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SicaGene.